Ramsay Health Care Limited Overview
FY22–FY24 figures are company statements of "over" 86,000 / 89,000 / 90,000 [S6][S5][S4]; FY26 is the analyst sum of divisional disclosures [S2]; a group-wide FY25 figure was not located.
Ramsay Health Care is Australia's largest private hospital operator and one of the world's larger listed private hospital groups, built over six decades on the founding ethos of "people caring for people." Its strategic centre of gravity is a 70-facility Australian network (including the managed Joondalup and Noosa public campuses) that admitted 1.24 million patients in FY26 and generated 55% of group underlying EBIT. Around this core sit two UK businesses — an NHS-dependent acute hospital chain (34 hospitals) and Elysium, a specialist mental health provider in turnaround — and a 52.79% controlling stake in Ramsay Santé, the Paris-listed European private hospital and primary care leader. Under CEO Natalie Davis (ex-Woolworths, ex-McKinsey), the company is pivoting from a diversified international holding structure to a focused, capital-disciplined Australian acute-care platform: closing sub-scale sites, lifting theatre utilisation, negotiating indexation-linked insurer contracts, acquiring selectively (National Capital Private Hospital, Canberra) and proposing to demerge Ramsay Santé by December 2026.
Company's own description (latest annual report)
In its FY26 Operating and Financial Review, Ramsay describes itself as a provider of quality healthcare services in a core Australian market, a UK presence comprising two businesses (Ramsay UK hospitals and Elysium mental health services), and a European presence through its 52.79% ownership of Ramsay Santé in France and the Nordics [S2]. The stated Australian vision is to be "Australia's most trusted leading healthcare provider" [S2]. Ramsay Australia's focus is described as operating private acute hospitals delivering complex care in priority therapeutic areas — cardiology, oncology, orthopaedics and psychology (mental health) — alongside mental health facilities, two managed public hospitals, hospital-in-the-home, telehealth, 31 allied health clinics and the Ramsay Pharmacy franchise network supporting 62 community pharmacies and 41 in-hospital dispensaries [S2].
Independent characterisation
Ramsay is an asset-heavy, labour-intensive healthcare services operator whose economics are governed by three variables: (i) activity and acuity (admissions, theatre utilisation, case mix), (ii) price indexation set by private health insurers (Australia), the NHS tariff (UK), local authorities and NHS commissioners (Elysium) and the French state (Santé), and (iii) labour cost inflation — employee and contractor costs consumed 57.2% of FY26 group revenue (A$10,703.0m of A$18,706.9m) [S2]. Ramsay has no product IP, no subscription base and no manufacturing; it monetises clinical capacity (beds, theatres, cath labs) staffed by employed nurses and allied health professionals and used by independent visiting medical officers (VMOs) who bring patients. Competitive advantage stems from network scale with insurers, owned freehold real estate (44 owned Australian facilities generated A$808.6m of EBITDAR in FY26 before overhead allocation [S3]), doctor relationships, and clinical reputation. The structural vulnerability is that Ramsay is a price-taker in most markets: payors' indexation has lagged cost inflation since 2021 in every geography, which is why margins have compressed from pre-COVID levels and why the current strategy prioritises utilisation, procurement and portfolio pruning rather than greenfield expansion.
Revenue model and mix (FY26)
| Revenue type, FY26 | AUD Mn | % of revenue from contracts | Source |
|---|---|---|---|
| Revenue from patients | 17,987.9 | 96.8 | [S2] |
| Revenue from ancillary services | 472.1 | 2.5 | [S2] |
| Rental revenue (e.g., medical suites) | 117.8 | 0.6 | [S2] |
| Revenue from contracts with customers | 18,577.8 | 100.0 | [S2] |
The model is overwhelmingly fee-for-service (episode-based or per-diem reimbursement). There is no subscription or licensing revenue. Within Australia, FY26 revenue comprised revenue from customers (hospital admissions and outpatients) A$5,254.1m, pharmacy A$626.3m and other (mainly prostheses and rental) A$913.2m [S2].
Value chain position and customers
Ramsay sits at the provider layer between payors and patients. Payor types: private health insurers (Australia; UK private medical insurers such as Bupa and VitalityHealth), governments and public health systems (WA Government at Joondalup; NHS England via e-referral and commissioning; local authorities for Elysium placements; French national health insurance; Swedish regions such as Region Stockholm at St Göran), self-pay patients, and the Department of Veterans' Affairs in Australia [S2][S3][S21]. End-markets: acute surgical and medical care, maternity, rehabilitation, inpatient mental health, secure and complex mental health care (UK), primary care and imaging (Europe), and retail/hospital pharmacy (Australia).
Payor mix indicators (FY26): In Australia, privately funded admissions grew 2.8% and publicly funded admissions (including public-in-private) grew 9.5% on a like-for-like basis [S2]. In Ramsay UK, NHS admissions were 72.6% of total admissions (74.8% in FY25), with private pay (insured plus self-pay) at 27.4% [S3][S2].
Strategy
Stated strategy (FY26 Annual Results / OFR)
Management frames its agenda around three CEO priorities [S3]:
-
Transform the market-leading Australian hospital business — under the "Ramsay 2030" strategy refreshed after Davis's arrival.
-
Strengthen capital discipline and improve capital returns across the portfolio — including the Ramsay Santé separation.
-
Evolve the culture of "people caring for people" to innovate and accelerate delivery.
Priority therapeutic areas (Australia): cardiology, orthopaedics and cancer care, with mental health retained as a core service line [S1][S2].
The "Big 5" Australian hospital operations initiatives [S3]
| Initiative | FY26 progress | FY27 plan |
|---|---|---|
| Growth | Admitting VMOs +3.3%; theatre utilisation ~+90bps to 70% while adding 22 rooms; catchment-based data insights; CRM; GP liaison and business development sales force uplift; higher robotics use | Catchment growth plans; ramp-up of new developments; National Capital integration |
| Procurement | Benefits ahead of target; supplies as % of revenue down ~50bps | "Switch and Save" data tool; food menu standardisation; rapid tendering of non-clinical categories |
| Revenue cycle management | Strong cash collection; cash conversion cycle -4 days | Admission digitisation; coding standardisation; claims generation efficiencies; upgraded Patient Administration System |
| Workforce | Record graduate intakes; national hiring to reduce agency | Agency reduction; skill mix; EBA negotiations; future rostering model |
| Technology and AI | Rollout of key hospital systems; pilot AI use cases | Smart Rostering and team app; procedural profitability analytics; contract management; prostheses tracking; AI use cases |
Strategic initiatives — last 24 months
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Ramsay Santé strategic review and proposed demerger | Feb 2025 (review) → Feb 2026 (proposal) → Nov 2026 (vote) | In-specie distribution of 52.79% stake; Santé CDIs to trade on ASX; shareholders' agreement with Crédit Agricole Assurances terminated effective 1 Oct 2026 | [S9][S8] |
| National Capital Private Hospital | Dec 2025 – Sep 2026 | A$251m debt-funded entry into ACT; expected top-20 hospital by revenue and profit; EPS-accretive in year one | [S12][S13] |
| Portfolio optimisation | FY26 | 4 Australian sites closed, surplus land for sale; Elysium 7 sites closed | [S3] |
| Payor model reform | FY25–FY26 | All major PHI negotiations completed with improved FY25–26 indexation; new multi-year partnership with a major insurer; four agreements with indexation linked to sector metrics | [S7][S3] |
| Bupa partnership expansion | May 2025 | Out-of-hospital pilots (home/virtual rehab, community mental health follow-up) | [S21] |
| Clinical trials network | FY26 | Ramsay Research and Development Network expanded to 22 sites; trials +28% | [S3] |
| Elysium turnaround | FY25–FY27 | Strategic diagnostic with external advisers (2025); three phases of central cost reduction (161 FTE); fee negotiation; site divestments | [S2] |
| Executive capability rebuild | 2,025 | New CFO, COO Australia, CCO Australia, Technology & Digital, Health & Strategy executives | [S15][S14b] |
| Office consolidation | FY26 | Global and Australian support offices merged at St Leonards | [S1] |
| Sustainability reset | Aug 2026 | Net zero (Scope 1+2) moved from 2040 to 2050; UK and Elysium Scope 3 net zero by 2050 | [S1] |
| Investor Day | 30 Nov 2026 (scheduled) | Group Executive to present progress and plans post-demerger vote | [S3] |
Medium-term targets and FY27 guidance
| Item | Guidance / target | Source |
|---|---|---|
| Funding Group EBIT | Growth and EBIT margin improvement in FY27 | [S1] |
| Australia | Incremental YoY EBIT growth (incl. and excl. National Capital) and margin expansion; includes A$10–15m higher IT/technology/transformation opex | [S1] |
| National Capital | EPS-accretive in first 12 months; transition opex A$9–11m (excluded from underlying, skewed to 1H) | [S1] |
| UK Hospitals / Elysium | EBIT growth in FY27 for both; Elysium plans for continued weak demand | [S1] |
| Funding Group net financing expense (incl. AASB 16) | A$280–300m | [S1] |
| Funding Group underlying effective tax rate | ~30% | [S1] |
| Funding Group capex | A$480–520m (Australia A$380–410m incl. A$6–10m National Capital) | [S1][S2] |
| Dividend payout | 60–70% of underlying group NPAT after NCI | [S1] |
| Leverage | Funding Group <2.5x (covenant 3.5x, or 4.0x if investment grade) | [S3] |
| Ramsay Santé (standalone) | "Connecting Care 2030" — five strategic pillars; solid organic growth targeted | [S11] |
Products & Services
Ramsay sells clinical services rather than products; the "catalog" below lists each service line and named flagship facilities. Pricing is set by payor contracts rather than list prices unless otherwise noted.
Australia
| Offering | Description and capability | Target customer / payor | Latest development | Pricing model |
|---|---|---|---|---|
| Acute private hospitals | Full-service surgical and medical hospitals with ICU/CCU, cath labs, emergency departments at selected sites. Flagships (licensed beds / theatres, procedure rooms and cath labs): Hollywood Private, Perth (950 / 30); Greenslopes Private, Brisbane (700 / 36); John Flynn Private, Gold Coast (358 / 18); North Shore Private, Sydney (351 / 27); Peninsula Private, Victoria (350 / 13); Pindara Private, Gold Coast (323 / 19); St George Private, Sydney (276 / 20); Warringal Private, Melbourne (252 / 19); Westmead Private, Sydney (216 / 17) [S3] | Privately insured patients; VMOs; DVA; public-in-private | Warringal ED opened 12 Aug 2026; Hollywood adding 2 theatres and 2 cath labs by Dec 2026; St George 2 cath labs due Q4 FY27 [S3] | Insurer Hospital Purchaser Provider Agreements (episode/per-diem) with annual indexation; four agreements now link indexation to sector metrics [S3] |
| Public-private campuses | Joondalup Health Campus, WA (796 beds / 25 rooms, public + private) operated under contract with WA Government; Noosa Hospital, QLD (public, 92 beds) [S3] | State governments | New Joondalup funding mechanism (March 2024) reduced FY26 EBIT by a net A$26m [S2] | Government activity-based/contracted funding |
| Day surgery and short-stay surgical centres | Ramsay Surgical Centres (Cairns, Miranda, Orange, Coffs Harbour, Charlestown, Cleveland), Short Street Day Surgery, Pindara Day Procedure Centre, Victorian Day Procedure Centre [S3] | PHI and self-funded day patients | Charlestown (6 rooms) and Caloundra opened FY26; Cleveland (3 theatres) opened Aug 2026; Campbelltown centre commencing [S3] | Episode-based PHI contracts |
| Emergency departments | Seven private EDs plus Joondalup and Noosa public EDs; EDs drive c.20% of overnight inpatient admissions [S3][S4] | Walk-in and referred patients | Warringal ED opened Aug 2026 [S3] | Patient fees plus downstream admissions |
| Mental health (inpatient and day) | Ramsay Clinics (e.g., New Farm 114 beds, Albert Road 123, Northside 137, Adelaide 91, Wentworthville, Macarthur, Cremorne, Cairns, Caloundra) [S3] | PHI members (gold-tier cover), DVA | FY26 mental health admissions -3.9% (day programs down; overnight +0.9%) as insured members down-tier from gold to silver [S3] | Per-diem PHI contracts |
| Rehabilitation hospitals | Donvale (85 beds), Mt Wilga (119), plus rehab wards across network | PHI, DVA, workers' compensation | Rehab admissions +3.8% FY26 [S2] | Per-diem |
| Maternity | e.g., Frances Perry House (Melbourne); remote foetal monitoring deployed at all maternity sites [S3] | PHI members | Flat maternity admissions FY26 [S2] | Episode-based |
| Oncology and infusion | Western Sydney Private Oncology and Infusion Centre; cancer care is a priority therapeutic area | PHI | Expanded service differentiation targeted [S2] | Episode/day fees |
| Hospital-in-the-home and telehealth | Out-of-hospital acute and post-acute care | PHI (incl. Bupa pilots) | Bupa agreement (May 2025) pilots home/virtual rehab and community mental health follow-up [S21] | Contracted packages |
| Allied health clinics | 31 clinics (physiotherapy etc.) [S2] | Patients, PHI extras | — | Fee-for-service |
| Ramsay Psychology | Community psychology practices (14 in FY24) | Medicare/self-pay | Majority of clinics closed in FY25 with A$16.3m impairment [S2][S4] | Fee-for-service |
| Ramsay Pharmacy | Franchise network supporting 62 community pharmacies and 41 in-hospital dispensaries | Retail customers; hospital patients | Revenue A$626.3m FY26, +5.7% [S2] | Retail/PBS dispensing; franchise fees |
| Ramsay Research and Development Network | National clinical trials capability across 22 sites | Sponsors, patients, clinicians | Trials activity +28% FY26 [S3] | Sponsor-funded |
| National Capital Private Hospital (Canberra) | 148 beds, 8 theatres, 1 cath lab, ICU/CCU; co-located with Canberra Hospital, adjacent to ANU Medical School; lease to 2064 | PHI, ACT catchment | Acquired 1 Sep 2026 for A$251m [S13][S12b] | PHI contracts |
| Patient amenities | "At Your Request" hospital dining being scaled nationally [S3] | Inpatients | Rollout FY26–FY27 | Included in episode |
United Kingdom — Ramsay UK
| Offering | Description | Customer | Latest development | Pricing |
|---|---|---|---|---|
| Acute independent hospitals and day procedure centres (34) | Orthopaedics, spinal, ophthalmology, general surgery, cancer care, diagnostics, physiotherapy | NHS e-referral patients (72.6% of admissions), PMI, self-pay | Average revenue per admission +6.7% FY26 on acuity and mix [S2]; Glendon Wood (Northamptonshire) opened Aug 2023; West Valley (Croydon) closed Jan 2024 [S4] | NHS national tariff (FY26/27 revised to 1.24%); PMI multi-year contracts; self-pay packages |
| Insurer partnership networks | Hip, knee, spinal and ophthalmic partnership networks with VitalityHealth; Bupa specialist cancer care centres (breast, bowel, prostate) | PMI members | VitalityHealth long-term agreement extended (Sep 2026); Bupa UK four-year contract [S21] | Negotiated network tariffs |
| Diagnostic imaging | Imaging service within network | NHS, PMI | Data centres written down FY24 [S4] | Fee-for-service |
United Kingdom — Elysium Healthcare
| Offering | Description | Customer | Latest development | Pricing |
|---|---|---|---|---|
| Secure mental health hospitals | Medium- and low-secure inpatient services | NHS England commissioners | Occupancy 86.1% FY26; June 2026 occupancy 87.2% [S3] | Per-bed daily fee; NHS tariff awards and spot negotiations; average daily fee +4.4% FY26 [S2] |
| Neurological rehabilitation and complex care | Neuro-rehab, complex care homes, learning disability and autism services | NHS, local authorities | Weak local authority demand; shift to community settings [S3] | Daily fees |
| Enhanced packages of care / complex recovery | Higher-acuity placements targeted for growth | NHS, local authorities | Conversion focus in FY27 [S2] | Premium daily fees |
| Educational settings | Residential and educational placements (per company description) | Local authorities | — | Placement fees |
| Portfolio | 88 sites, c.2,196 beds; 7 sites closed and 239 beds removed in FY26; 5 sites held for sale | — | Turnaround under CEO Joe O'Connor (from Jan 2026) [S2][S3] | — |
Europe — Ramsay Santé (52.79% owned; proposed for demerger)
| Offering | Description | Customer | Latest development | Pricing |
|---|---|---|---|---|
| France — MSO acute care | Medicine, surgery, obstetrics; c.150 hospitals historically | French national health insurance; complementary insurers | MSO admissions +2.5% FY26; targeted maternity closures [S2][S3] | Regulated DRG tariffs (0.5% for 2025, 0% for 2026) less 0.7% prudential coefficient withheld [S2] |
| France — follow-up care and rehabilitation (FCR/SMR) and mental health | Post-acute and psychiatric facilities | National health insurance | Allocation-based funding model [S4] | Regulated |
| Imaging and radiotherapy | 11 new imaging equipment sites installed FY26 | Patients, referrers | Strategic higher-margin value pool [S2] | Regulated fees |
| Primary care (France) | Cosem medical centres (12 acquired June 2024) | Patients | Integration into care pathways [S4] | Regulated fees |
| Nordics — Capio (Sweden, Norway, Denmark) | Primary care (Proximity Care), specialist clinics, orthopaedics, elderly care, St Göran acute hospital (Stockholm) | Regional governments, insurers | St Göran 8+4-year contract from 5 Jan 2026 on improved terms; €26m refundable deposit paid [S2][S3] | Regional contracts |
| Italy | 93-bed hospital | Italian payors | — | — |
| Scale | 487 facilities in 5 countries; 40,000+ employees; 13m patients per year [S2] | — | "Connecting Care 2030" strategy (Sep 2026) [S11] | — |
Financial Narrative
Basis of preparation: FY22 figures are as originally reported (Ramsay Sime Darby equity-accounted within continuing operations) [S6]; FY23 figures are as restated in the FY24 Appendix 4E with RSD treated as discontinued [S4]; FY24 from FY24 Appendix 4E [S4]; FY25–FY26 from FY26 Appendix 4E [S2]. "Underlying" figures exclude items the company classifies as non-recurring (impairments, restructuring, transaction costs, asset-sale gains). All values A$m unless stated.
Income statement
Notes: Gross profit is not a reported metric for Ramsay; the proxy deducts "medical consumables and supplies" from total revenue and other income (including interest income) and is an analyst construct. FY22 underlying EBIT = reported EBIT A$891.3m plus A$60.1m negative non-recurring items [S6] and includes Ramsay's share of RSD profit (A$15.3m). FY23 underlying EBIT = A$1,001.4m less A$42.1m positive non-recurring items [S4]. FY24 statutory NPAT includes the A$618.1m RSD sale profit [S4]. FY25 statutory NPAT includes a A$291m post-tax UK impairment [S2].
Margins and growth
Analyst calculations on total revenue and other income less interest income (margins) and total revenue including interest (employee cost ratio) from [S2][S4]. Revenue CAGR FY22–FY26: 8.0% p.a. (reported A$); FY23–FY26: 6.8% p.a. FY26 constant-currency revenue growth was 4.2% [S2].
Commentary — income statement. The five-year arc has three phases. FY22–FY23 (COVID hangover and acquisition-led growth): revenue rose 11.6% in FY23 largely from full-year contributions of Elysium and GHP (A$767m) [S5], but margin recovery was choked by labour shortages, agency usage and inflation, while net financing costs (excluding AASB 16) doubled as base rates rose [S5]. FY24–FY25 (margin trough and write-downs): underlying EBIT edged up, but Ramsay Santé's EBIT fell 33% in local currency as French tariffs (0.3% initial 2024 indexation) and withdrawn COVID support eroded margins [S4], and Elysium's deterioration forced the A$305m UK impairment in 1H FY25 [S2]. Statutory NPAT swung from A$888.7m (RSD gain) to A$24.0m. FY26 (inflection): underlying EBIT rose 11.8% cc and underlying NPAT 22.9% cc, the first year in which all regions grew EBIT [S1]. The drivers were Australian indexation finally exceeding cost inflation, +90bps theatre utilisation, ~50bps procurement savings on supplies, Elysium cost-outs and the St Göran contract [S3]. Underlying EBIT margin (6.2%) is nonetheless still below FY22's 6.9% and well below pre-COVID levels; the operating leverage case remains a work in progress. The underlying effective tax rate rose to 35.9% (32.7% FY25) because Ramsay Santé is loss-making before tax yet pays French CVAE [S2], a drag that disappears on demerger (Funding Group rate ~29–30%).
Balance sheet
Sources: [S2][S4]; FY22 balance items from the FY24 Appendix 4E reconciliation of financing liabilities and statement of changes in equity (opening 1 July 2022 balances) [S4]. Net debt excluding leases for FY22–FY24 is an analyst calculation (borrowings less cash); FY23–FY24 company-reported net debt including derivatives was A$5,147.2m and A$4,376.1m [S4]. Goodwill is not separately disclosed in the reviewed summaries; intangibles are predominantly goodwill (the UK goodwill write-down of A$248.4m in FY25 [S2]).
Commentary — balance sheet. The defining feature is the dual-balance-sheet structure: Ramsay Santé carries non-recourse secured debt of roughly €1.6bn (bank net debt, IAS 17 basis) at 4.7x leverage, while the Funding Group carries A$1.9bn of net debt at 1.83x [S3]. Consolidated net debt including leases of A$10.3bn therefore overstates the risk to Ramsay shareholders; roughly 55% of consolidated lease liabilities (A$3.49bn) and 58% of net bank debt (A$2.65bn) sit inside Ramsay Santé [S3]. The RSD sale in December 2023 cut Funding Group leverage from 3.22x to 2.00x [S4]. In FY26 a ~A$300m adverse currency translation and the Elysium portfolio restructure (A$300m reduction in right-of-use assets and leases) shrank the balance sheet [S2]. Negative working capital is structural for a hospital operator (creditors and employee provisions exceed receivables). Net tangible assets are negative (–A$2.9 per share including right-of-use assets) [S2].
Cash flow
Sources [S2][S4]. FY22 OCF is derived from the FY23 disclosure that OCF rose 78.8% to A$1,279.6m [S5]. No on-market buybacks occurred FY23–FY26 per statements of changes in equity [S2][S4].
Commentary — cash flow. The most important FY26 data point is not consolidated cash flow (down 3.4% because of the timing of French government receipts in Ramsay Santé) but the 46% jump in Funding Group operating cash flow to A$869.1m and the near-sevenfold rise in Funding Group free cash flow to A$382.4m [S2]. That reflects revenue-cycle discipline (Australian cash conversion cycle shortened by 4 days), capex restraint (Funding Group capex down 9% to A$487.9m cc) and the absence of the prior year's tax on the RSD gain [S3]. On a consolidated basis, after lease principal (a real economic cost under AASB 16), free cash flow was only A$104m in FY26 — less than half the dividend — underscoring why separating the cash-consuming Ramsay Santé structure flatters the remaining group's cash profile.
Returns, leverage and efficiency ratios
Notes: Company-reported ratios from [S2][S3][S4]; others are analyst calculations. Payout ratios: FY22 analyst (DPS/diluted EPS); FY23 on statutory NPAT; FY24 on continuing basic EPS; FY25 on underlying continuing NPAT; FY26 on underlying NPAT [S5][S4][S7][S2]. FY23 tax rate shown on restated continuing basis (34.4%); FY23 as originally reported was 33.2% [S5][S4] — source discrepancy noted. A formal cash conversion cycle is not disclosed; the company states only that Australia's cycle improved 4 days in FY26 [S3]; receivables days are an analyst proxy.
Commentary — ratios. Return metrics are low in absolute terms (accounting ROIC 4.6%) because of the large goodwill and lease base, but the Funding Group's ROCE of 14.8% (up 150bps) demonstrates that the Australia/UK perimeter earns comfortably above its cost of capital on tangible capital [S2]. Reported interest coverage of 1.8x looks thin only because consolidated finance costs include A$290m of lease interest and Ramsay Santé's high-cost secured debt; the covenant interest cover of 8.94x is the relevant solvency test. The step-change in receivables days (55 to 45) reflects collection focus and the Ramsay Santé timing of French government payments, and supports management's revenue-cycle narrative.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key operating facts (FY26) |
|---|---|---|
Australia | 70 hospitals, clinics and day surgery units incl. managed Joondalup and Noosa public campuses; mental health clinics; 31 allied health clinics; hospital-in-the-home; telehealth; Ramsay Pharmacy (62 community pharmacies, 41 in-hospital dispensaries); global head office | 1.24m admissions; 36,000+ employees; underlying EBIT margin 9.4% [S2] |
UK — Ramsay UK | 34 acute hospitals and day procedure centres serving NHS, insured and self-pay patients | 218,900 admissions; 7,500+ employees; underlying EBIT margin 10.2% [S3][S2] |
UK — Elysium | Specialist mental health, neurological and care services across England and Wales; 88 sites, c.2,196 beds | 1,981 average paid beds; 86.1% occupancy; c.8,900 employees [S2][S3] |
Europe — Ramsay Santé (France) | Acute (MSO), follow-up and rehabilitation, mental health, imaging, primary care; plus a 93-bed hospital in Italy | Underlying EBIT A$206.7m, down 7.4% cc [S2] |
Europe — Ramsay Santé (Nordics) | Sweden (incl. St Göran, Proximity Care primary care, orthopaedics, elderly care), Norway, Denmark | Underlying EBIT A$124.1m, up 65.6% cc [S2] |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia revenue (AUD Mn) | 5,711.0 | 6,061.6 | 6,322.7 | 6,818.1 |
UK revenue (AUD Mn) | 1,941.2 | 2,360.8 | 2,661.7 | 2,605.0 |
of which Ramsay UK revenue (AUD Mn) | 1,148.7 | 1,401.7 | 1,568.7 | 1,567.4 |
of which Elysium revenue (AUD Mn) | 792.5 | 959.1 | 1,093.0 | 1,037.6 |
France revenue (AUD Mn) | 5,291.2 | 5,764.2 | 6,098.0 | 6,334.0 |
Nordics revenue (AUD Mn) | 2,395.7 | 2,593.6 | 2,704.8 | 2,941.5 |
Total segment revenue (AUD Mn) | 15,339.1 | 16,780.2 | 17,787.2 | 18,698.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia revenue growth (%) | 6.1 | 4.3 | 7.8 |
UK revenue growth reported A$ (%) | 21.6 | 12.7 | -2.1 |
France revenue growth reported A$ (%) | 8.9 | 5.8 | 3.9 |
Nordics revenue growth reported A$ (%) | 8.3 | 4.3 | 8.8 |
Segment share of total segment revenue (%)
| Segment share of total segment revenue (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Australia share (%) | 37.2 | 36.1 | 35.5 |
UK share (%) | 12.7 | 14.1 | 15.0 |
France share (%) | 34.5 | 34.4 | 34.3 |
Nordics share (%) | 15.6 | 15.5 | 15.2 |
Results by Segment
| Segment metric (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia EBITDA (AUD Mn) | 786.3 | 802.4 | 816.6 | 892.7 |
UK EBITDA (AUD Mn) | 206.3 | 314.0 | 317.2 | 347.4 |
France EBITDA (AUD Mn) | 751.3 | 735.2 | 760.0 | 743.6 |
Nordics EBITDA (AUD Mn) | 258.3 | 274.1 | 265.6 | 324.9 |
Australia reported EBIT (AUD Mn) | 556.5 | 572.5 | 560.2 | 629.9 |
UK reported EBIT (AUD Mn) | 63.8 | 160.6 | -144.3 | 176.9 |
France reported EBIT (AUD Mn) | 293.7 | 191.6 | 218.6 | 184.6 |
Nordics reported EBIT (AUD Mn) | 87.4 | 72.9 | 71.7 | 114.0 |
Australia underlying EBIT (AUD Mn) | 542.6 | 569.3 | 575.5 | 639.8 |
UK underlying EBIT (AUD Mn) | 78.7 | 175.4 | 169.3 | 191.6 |
Europe underlying EBIT (AUD Mn) | 338.0 | 289.3 | 297.8 | 330.8 |
Underlying EBIT margin by region (%)
| Underlying EBIT margin by region (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia underlying EBIT margin (%) | 9.5 | 9.4 | 9.1 | 9.4 |
UK underlying EBIT margin (%) | 4.1 | 7.4 | 6.4 | 7.4 |
Europe underlying EBIT margin (%) | 4.4 | 3.5 | 3.4 | 3.6 |
Results by Segment and Segment Margins & Growth (%)
| Business unit metric | FY2025 | FY2026 |
|---|---|---|
Ramsay UK underlying EBIT (AUD Mn) | 147.3 | 160.5 |
Elysium underlying EBIT (AUD Mn) | 22.0 | 31.1 |
France underlying EBIT (AUD Mn) | 224.0 | 206.7 |
Nordics underlying EBIT (AUD Mn) | 73.8 | 124.1 |
Ramsay UK underlying EBIT margin (%) | 9.4 | 10.2 |
Elysium underlying EBIT margin (%) | 2.0 | 3.0 |
Ramsay Santé underlying loss after tax and NCI attributable to Ramsay (AUD Mn) | -39.9 | -34.3 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total revenue and other income less interest income (AUD Mn) | 13,740.0 | 15,329.3 | 16,772.1 | 17,779.3 | 18,690.3 |
Revenue from contracts with customers (AUD Mn) | — | 14,963.9 | 16,660.2 | 17,673.8 | 18,577.8 |
Gross profit proxy: total revenue less medical consumables (AUD Mn) | — | 12,021.5 | 13,065.7 | 13,849.5 | 14,578.2 |
EBITDAR (AUD Mn) | — | 2,149.6 | 2,276.4 | 2,323.5 | 2,469.1 |
EBITDA reported (AUD Mn) | — | 2,002.2 | 2,125.7 | 2,159.4 | 2,308.6 |
Underlying EBITDA (AUD Mn) | — | — | — | 2,168.9 | 2,343.4 |
EBIT reported (AUD Mn) | 891.3 | 1,001.4 | 997.6 | 706.2 | 1,105.4 |
Underlying EBIT (AUD Mn) | 951.4 | 959.3 | 1,034.0 | 1,042.6 | 1,162.2 |
Net finance costs incl. lease interest (AUD Mn) | — | 474.3 | 613.0 | 604.4 | 591.8 |
Profit before tax (AUD Mn) | 538.5 | 527.1 | 384.6 | 101.8 | 513.6 |
Income tax expense (AUD Mn) | 159.3 | 181.5 | 121.3 | 55.5 | 192.2 |
NPAT attributable to owners, statutory (AUD Mn) | 274.0 | 298.1 | 888.7 | 24.0 | 329.2 |
NPAT from continuing operations attributable (AUD Mn) | — | 278.2 | 270.6 | 24.0 | 329.2 |
Underlying NPAT attributable (AUD Mn) | — | 250.7 | 300.1 | 305.3 | 364.1 |
Basic EPS after CARES dividend (cents) | — | 125.1 | 381.6 | 3.0 | 136.2 |
Diluted EPS after CARES dividend (cents) | 116.1 | 124.8 | 380.9 | 3.0 | 135.8 |
Underlying diluted EPS (cents) | — | — | — | 125.3 | 151.0 |
Dividends per share (cents) | 97.0 | 75.0 | 80.0 | 80.0 | 91.0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY reported (%) | — | 11.6 | 9.4 | 6.0 | 5.1 |
EBITDA margin reported (%) | — | 13.1 | 12.7 | 12.1 | 12.4 |
EBIT margin reported (%) | 6.5 | 6.5 | 5.9 | 4.0 | 5.9 |
Underlying EBIT margin (%) | 6.9 | 6.3 | 6.2 | 5.9 | 6.2 |
Statutory net margin (%) | 2.0 | 1.9 | 5.3 | 0.1 | 1.8 |
Underlying net margin (%) | — | 1.6 | 1.8 | 1.7 | 1.9 |
Employee and contractor costs to total revenue (%) | — | 57.4 | 57.5 | 57.4 | 57.2 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | 21,030.2 | 20,894.0 | 22,475.5 | 20,824.8 |
Cash and cash equivalents (AUD Mn) | 314.2 | 656.1 | 662.3 | 784.4 | 729.9 |
Borrowings — current (AUD Mn) | 42.8 | 69.9 | 134.1 | 78.5 | 84.2 |
Borrowings — non-current (AUD Mn) | 5,173.5 | 5,861.5 | 4,949.9 | 5,458.4 | 5,209.6 |
Total borrowings (AUD Mn) | 5,216.3 | 5,931.4 | 5,084.0 | 5,536.9 | 5,293.8 |
Lease liabilities (AUD Mn) | 5,482.4 | 5,954.9 | 5,854.1 | 6,583.0 | 5,704.7 |
Net debt excl. leases and derivatives (AUD Mn) | 4,902.1 | 5,275.3 | 4,421.7 | 4,752.5 | 4,563.9 |
Net debt incl. leases, company definition (AUD Mn) | — | 11,102.1 | 10,230.2 | 11,335.5 | 10,268.6 |
Funding Group net debt excl. leases (AUD Mn) | — | 2,664.4 | 1,833.3 | 2,028.9 | 1,912.8 |
Total equity (AUD Mn) | 4,526.2 | 4,823.2 | 5,527.5 | 5,708.7 | 5,593.8 |
Equity attributable to parent (AUD Mn) | 3,933.5 | 4,154.8 | 4,897.6 | 5,023.6 | 4,956.0 |
Non-controlling interests (AUD Mn) | 592.7 | 668.4 | 629.9 | 685.1 | 637.8 |
Intangible assets incl. goodwill (AUD Mn) | — | 6,163.7 | 6,139.9 | 6,431.1 | 5,975.5 |
Property, plant and equipment (AUD Mn) | — | 5,238.1 | 5,383.6 | 5,820.0 | 5,701.4 |
Right-of-use assets (AUD Mn) | — | 4,949.1 | 4,775.4 | 5,333.0 | 4,429.8 |
Total current assets (AUD Mn) | — | 3,895.8 | 3,872.8 | 4,040.3 | 3,704.9 |
Total current liabilities (AUD Mn) | — | 3,810.4 | 4,180.3 | 4,465.6 | 4,065.7 |
Working capital: current assets less current liabilities (AUD Mn) | — | 85.4 | -307.5 | -425.3 | -360.8 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | 715.7 | 1,279.6 | 1,292.8 | 1,480.8 | 1,430.7 |
Capital expenditure (AUD Mn) | — | 720.9 | 753.8 | 776.6 | 734.2 |
Free cash flow: OCF less capex (AUD Mn) | — | 558.7 | 539.0 | 704.2 | 696.5 |
Lease principal repaid (AUD Mn) | — | 403.2 | 450.5 | 508.8 | 592.1 |
Free cash flow after lease principal (AUD Mn) | — | 155.5 | 88.5 | 195.4 | 104.4 |
Dividends paid to parent shareholders (AUD Mn) | — | 218.7 | 134.9 | 161.6 | 205.7 |
Dividends paid incl. non-controlling interests (AUD Mn) | — | 236.8 | 158.3 | 190.7 | 238.0 |
Share buybacks (AUD Mn) | — | 0 | 0 | 0 | 0 |
Shares issued under DRP (AUD Mn) | — | 18.8 | 30.4 | 39.1 | 0 |
Funding Group operating cash flow (AUD Mn) | — | — | — | 595.7 | 869.1 |
Funding Group free cash flow (AUD Mn) | — | — | — | 58.7 | 382.4 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE statutory on closing parent equity (%) | 7.0 | 7.2 | 18.1 | 0.5 | 6.6 |
ROE underlying on closing parent equity (%) | — | 6.0 | 6.1 | 6.1 | 7.3 |
ROA: total NPAT on closing total assets (%) | — | 1.7 | 4.2 | 0.2 | 1.5 |
Accounting ROIC, company (%) | — | 4.3 | 4.3 | 4.3 | 4.6 |
Cash ROIC, company (%) | — | 10.9 | 11.7 | 11.5 | 11.9 |
Group ROCE, company (%) | — | — | — | 9.9 | 11.0 |
Funding Group ROCE, company (%) | — | — | — | 13.3 | 14.8 |
Current ratio (x) | — | 1.02 | 0.93 | 0.90 | 0.91 |
Borrowings to equity (x) | 1.15 | 1.23 | 0.92 | 0.97 | 0.95 |
Borrowings plus leases to equity (x) | 2.36 | 2.46 | 1.98 | 2.12 | 1.97 |
Net debt incl. leases to EBITDA, company (x) | — | 5.5 | 3.7 | 5.3 | 4.5 |
Net debt excl. leases to reported EBITDA (x) | — | 2.6 | 2.1 | 2.2 | 2.0 |
Funding Group covenant leverage (x) | — | 3.22 | 2.00 | 2.18 | 1.83 |
Interest coverage: EBIT over finance costs (x) | — | 1.9 | 1.6 | 1.1 | 1.8 |
Funding Group interest cover, covenant basis (x) | — | — | — | 8.93 | 8.94 |
Asset turnover: revenue over closing total assets (x) | — | 0.73 | 0.80 | 0.79 | 0.90 |
Receivables days on revenue from contracts (days) | — | 55.3 | 55.1 | 51.8 | 44.6 |
Effective tax rate reported (%) | 29.6 | 34.4 | 31.5 | 54.5 | 37.4 |
Dividend payout ratio (%) | 83.5 | 60.0 | 72.0 | 63.7 | 60.3 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia revenue (AUD Mn) | 5,711.0 | 6,061.6 | 6,322.7 | 6,818.1 |
United Kingdom revenue (AUD Mn) | 1,941.2 | 2,360.8 | 2,661.7 | 2,605.0 |
France revenue (AUD Mn) | 5,291.2 | 5,764.2 | 6,098.0 | 6,334.0 |
Nordics revenue (AUD Mn) | 2,395.7 | 2,593.6 | 2,704.8 | 2,941.5 |
APAC total incl. Australia (AUD Mn) | 5,711.0 | 6,061.6 | 6,322.7 | 6,818.1 |
EMEA total: UK + France + Nordics (AUD Mn) | 9,628.1 | 10,718.6 | 11,464.5 | 11,880.5 |
Revenue by Region — UK total revenue and other income
| Region (local currency) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
UK total revenue and other income (GBP Mn) | 1,083.0 | 1,229.0 | 1,330.7 | 1,315.8 |
Europe total revenue and other income (EUR Mn) | 4,924.3 | 5,065.2 | 5,233.8 | 5,400.2 |
Europe patient revenue (EUR Mn) | 4,466.4 | 4,792.1 | 4,998.5 | 5,181.0 |
Europe EBITDA (EUR Mn) | 643.6 | 612.4 | 608.5 | 624.6 |
UK underlying EBIT (GBP Mn) | — | — | 84.8 | 97.3 |
Europe underlying EBIT (EUR Mn) | — | — | 175.4 | 195.5 |
Region growth
| Region growth | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia revenue growth (%) | 6.1 | 4.3 | 7.8 |
UK revenue growth GBP (%) | 13.5 | 8.3 | -1.1 |
Europe revenue growth EUR (%) | 2.9 | 3.3 | 3.2 |
Share Price & Returns
| Reference point | Price (AUD) | Source |
|---|---|---|
24 Aug 2023 (post FY23 result) | 48.71 | [S18] |
30 Aug 2024 (post FY24 result, intraday) | 41.17 | [S34] |
Start of CY2025 | 34.05 | [S33] |
End of CY2025 | 34.36 | [S33] |
52-week low | 30.39 | [S18] |
26 Feb 2026 (post 1H result) | 42.12 | [S18] |
30 Jun 2026 (FY26 end) | 43.98 | [S33] |
27 Aug 2026 (post FY26 result close) | 50.06 | [S18] |
10 Sep 2026 (multi-year high) | 54.11 | [S18] |
7 Oct 2026 | 54.55 | [S18] |
Return metric | Value | Basis |
Year-to-date 2026 | ~+58% | 34.43 → 54.55 |
1-year (approx.) | ~+55% | vs ~A$35 traded in Nov 2025 [S17] |
~3-year | ~+12% | vs A$48.71 (Aug 2023) |
5-year | Negative (exact figure n.d.) | Shares traded at ~A$80+ during the April 2022 KKR approach [S27] |
FY2026 (Jul 2025–Jun 2026) | +19.4% | [S33] |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | A$12.6bn | 230.8m shares |
P/E statutory FY26 | 40.1x | Basic EPS 136.2c |
P/E underlying FY26 | 36.1x | Underlying diluted EPS 151.0c |
EV (ex leases) | ~A$18.0bn | Mkt cap + net debt A$4,564m + NCI A$638m + CARES A$252m |
EV (incl. leases) | ~A$23.7bn |
|
EV/EBITDA (incl. leases, FY26 reported) | ~10.3x | A$2,308.6m |
EV/Sales (incl. leases) | ~1.27x | A$18,690m |
P/B | ~2.5x | Parent equity A$4,956m |
Dividend yield (fully franked) | 1.7% | 91c |
Implied Funding Group P/E (ex-Santé stake ~A$1.1bn) | ~30x | Funding Group underlying NPAT after CARES ~A$383m |
Consensus forward P/E (aggregator) | ~31x FY27, ~27x FY28 | [S34] |
Peer multiples (Spire, etc.) | n.d. in reviewed sources | — |
Per-Share Data and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim DPS (cents) | 48.5 | 50.0 | 40.0 | 40.0 | 42.5 |
Final DPS (cents) | 48.5 | 25.0 | 40.0 | 40.0 | 48.5 |
Total DPS (cents) | 97.0 | 75.0 | 80.0 | 80.0 | 91.0 |
Franking (%) | 100 | 100 | 100 | 100 | 100 |
Final CARES dividend (A$ per CARES) | 2.055 | 3.061 | 3.30 | 3.07 | 3.36 |
Group Entities
| Entity | Agency | Rating / outlook |
|---|---|---|
Ramsay Health Care (Funding Group) | Fitch | BBB- / Stable (affirmed) |
Ramsay Health Care | Moody's, S&P | Not rated / n.d. |
Ramsay Santé | Moody's | B1 / Negative |
Ramsay Santé | S&P | B+ / Stable |
Analyst Conclusions
Management guidance (FY27)
Funding Group EBIT growth and margin improvement; Australian EBIT growth with margin expansion (incl. and excl. National Capital); EBIT growth at Ramsay UK and Elysium; Funding Group net finance costs A$280–300m; underlying tax ~30%; capex A$480–520m; payout 60–70% [S1]. Ramsay Santé to be treated as discontinued in FY27 if the demerger is approved [S2].
Consensus expectations
Aggregator data imply forward P/E of ~31x FY27 and ~27x FY28, consistent with mid-teens EPS growth expectations [S34]; detailed consensus EPS/revenue for the post-demerger perimeter is n.d.
Bull case
-
Pure-play re-rating: Removing a loss-making, 4.7x-levered subsidiary lifts group EPS (Funding Group underlying NPAT A$398m vs consolidated A$364m), lowers the tax rate to ~30% and improves ROCE optics to ~15% [S2].
-
Operating leverage in Australia: utilisation at 70% with a 30-point spread between lowest- and top-quartile sites, plus 11 new rooms in FY27 and indexation-linked insurer contracts, can sustain double-digit EBIT growth [S3].
-
Competitor dislocation: Healthscope's break-up and conversion to not-for-profit ownership may shift VMOs and insurer bargaining power toward the largest, best-capitalised operator [S22].
Bear case
-
Valuation already discounts recovery: ~36x underlying P/E and a share price above the average analyst target leave little margin for execution slippage [S18].
-
UK drag persists: NHS commissioning cuts and wage inflation could stall Ramsay UK and keep Elysium near break-even returns (ROCE 3.4%), with further impairment risk [S2].
-
Payor pushback: insurer payout ratios recovering toward 88% may prompt tougher future indexation, while down-tiering erodes mental health and maternity volumes [S3].
Key catalysts and monitorables (next 12 months)
-
Release of Demerger Booklet and independent expert's conclusion (Oct 2026); scheme vote and AGM (24 Nov 2026); implementation (Dec 2026) and initial ASX trading of Santé CDIs.
-
Investor Day (30 Nov 2026) — potential medium-term margin/ROCE targets for "new Ramsay".
-
1H FY27 result (Feb 2027): Australian margin trajectory, National Capital integration, Elysium EBIT.
-
PHI contract renewals and indexation; APRA payout-ratio data.
-
NHS 2027/28 tariff and elective commissioning budgets.
-
Paul Ramsay Foundation sell-down cadence; any capital management (buyback/DRP reinstatement) post-demerger.
-
Healthscope ownership transfer to Calvary-led consortium (by 30 Nov 2026).
Concluding analyst verdict
Ramsay Health Care is mid-way through the most consequential reshaping since its 2014 entry into France. FY26 marked a genuine operational inflection: every region grew EBIT, the Australian franchise delivered 11.2% underlying EBIT growth with margin expansion, the Funding Group's free cash flow multiplied almost sevenfold, and leverage fell to 1.83x. Management's priorities — utilisation over greenfield, procurement and revenue-cycle discipline, indexation-linked payor contracts and portfolio pruning — are coherent, measurable and showing early returns, and the rebuilt executive team has credible operating pedigrees.
The proposed demerger of Ramsay Santé is strategically sound. Santé contributes almost 30% of EBIT but nothing to Ramsay's bottom line after interest and minorities, consumes management attention, inflates the tax rate and obscures the quality of the Australian business. Post-separation, Ramsay becomes a simpler, investment-grade, Australia-centric hospital operator with a mid-teens ROCE and a UK option.
The debate is valuation and durability. After a ~58% year-to-date rally, the shares trade around 36x underlying FY26 EPS (roughly 30x on the Funding Group perimeter), above average analyst targets, implicitly pricing several years of double-digit earnings growth. That outcome requires continued above-inflation PHI indexation, further utilisation gains, a successful Elysium turnaround in a contracting market and no renewed NHS shock — while labour costs remain the swing factor everywhere. Margins also remain below pre-COVID levels, so the recovery is far from complete, but the market is now paying for it.
Verdict: fundamentally improving, strategically well-positioned, but fully valued near term. The risk/reward is balanced; the November 2026 vote and the 30 November Investor Day are the next decisive tests. A constructive stance on business quality is warranted, with entry discipline on valuation — monitor 1H FY27 Australian margins and Elysium cash generation as the key confirmation signals.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles and education |
|---|---|---|---|
Natalie Davis | Managing Director and Group CEO; Chair of Ramsay Générale de Santé | Joined Oct 2024; CEO from 2 Dec 2024 | MD Woolworths Supermarkets (130,000 staff, >A$46bn revenue); Chief Customer Transformation Officer and MD Woolworths NZ; 15 years McKinsey partner (ANZ/UK); MBA INSEAD; BCom/LLB (First Class Hons, University Medal), University of Sydney; former NED Quantium |
Anthony Neilson | Group CFO / Group Executive Finance; Director of Ramsay Santé | From 24 Nov 2025 | Santos: CFO (5 yrs) then Chief Commercial Officer (3+ yrs); CEO and CFO of Roc Oil; MBA AGSM (UNSW); Fellow CA ANZ |
Stuart Winters | Chief Operating Officer, Australia | n.d. (appointed during FY26 executive rebuild) | Led Sodexo's US Healthcare and Senior Living businesses; CEO Sodexo UK and Ireland |
Andrew Coombs | Chief Commercial Officer, Australia | Appointed ~Nov 2025 | VP Commercial, HCA Healthcare UK; MD AXA Global Health; CEO AXA Global Protect; KPMG |
Dr Brindan Suresh | Group Executive Health & Strategy | — | McKinsey Partner (health systems); NSW Health doctor; MBBS, LLB (Hons I), BA, University of Sydney |
Dr John Doulis | Group Executive Technology & Digital | Appointed ~Nov 2025 | VP and Distinguished Architect, HCA Healthcare digital transformation; CIO/Informatics leader, Vanderbilt University Medical Center; Monash medical graduate |
Colleen Harris | Group Executive People | Since 2018 | Senior HR roles at NAB, Federation Centres, MyState |
Henrietta Rowe | Group Executive Legal & Company Secretariat; Director of Ramsay Santé | Since June 2019 | Herbert Smith Freehills; Commonwealth Bank; LLB/BEc (Hons I), Sydney |
Nick Costa | Managing Director, Ramsay UK | MD since Jan 2022 | Ramsay UK COO for 4 years |
Joe O'Connor | Managing Director/CEO, Elysium Healthcare | From Jan 2026 | — |
Pascal Roché | Managing Director (CEO), Ramsay Santé | Since 2011 | Chairman, Ramsay Santé Corporate Foundation |
Board of Directors
| Director | Role | Appointed | Notes |
|---|---|---|---|
David Thodey | Independent Non-Executive Chairman; chairs Governance Committee | Board Nov 2017; Chair since 2023 | Chair of Xero; Chancellor, University of Sydney; former Telstra CEO |
Natalie Davis | Managing Director and Group CEO | 2 Dec 2024 | Executive |
Michael Siddle | Non-Executive Director (founding director) | Director since 1975 | Chairman 2014–2023; retiring at end of 2026 AGM (24 Nov 2026) |
Alison Deans | Non-Executive Director | — | Chair of Cochlear and Calix; technology/digital background |
Karen Penrose | Non-Executive Director; chairs Audit Committee | — | 30+ years finance, property, healthcare, resources; professional NED since 2014 |
Steven Sargent | Non-Executive Director; chairs Risk Management Committee | — | Multi-industry international experience incl. healthcare and energy |
Helen Kurincic | Non-Executive Director | — | Chair of McMillan Shakespeare; healthcare operator background |
Craig Drummond | Non-Executive Director | 1 Jul 2025 | Chair of Transurban, AFIC and The Ian Potter Foundation |
Dr Tracey Batten | Incoming Non-Executive Director | From 1 Jan 2027 | 30+ years healthcare; NED Medibank (retiring Nov 2026) and Nanosonics |
Dr Claudia Süssmuth Dyckerhoff | Former NED | Oct 2018 – 31 Aug 2026 (retired) | Risk Management Committee |
James McMurdo | Former NED | 2019 – Nov 2025 (retired) | Audit Committee |
Directors' Remuneration
| Item | Detail |
|---|---|
CEO fixed remuneration (appointment terms) | A$1.8m per annum |
CEO STI target | 100% of fixed remuneration |
CEO LTI | Annual grant up to 150% of fixed remuneration in performance rights |
CEO FY25 total remuneration (partial year) | c.A$2.73m (37.9% salary) per data aggregator |
CEO FY26 statutory remuneration | n.d. (FY26 Annual Report remuneration table not located during review) |
Other KMP remuneration | — |
2025 AGM remuneration report vote | Passed with 80.5% support (19.5% against — below the 25% "strike" threshold) |
Major Shareholders
| Holder | Stake | Date |
|---|---|---|
Paul Ramsay Holdings Pty Ltd (Paul Ramsay Foundation) | 16.4% (37,964,360 shares; reduced from 17.578%) | 31 Jul 2026 / notice 8 Jul 2026 |
Orbis Investment Management | Purchased 4.41m shares Feb 2025; current % n.d. | Feb 2025 |
Australian Foundation Investment Company | Listed among top holders; % n.d. | — |
BlackRock, Vanguard, State Street and other index funds | Present on register; current % n.d. | — |
Top-10 institutional holders with percentages | n.d. in reviewed primary sources; historical aggregator data suggested top 25 holders own ~62% | — |
Insider ownership — Natalie Davis | ~0.02% | 2025 |
Directors' on-market purchases (Sep 2024) | Thodey 2,475 shares; Kurincic 2,000; Penrose 1,225 | Sep 2024 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Ownership | Comparative scale | Positioning vs Ramsay |
|---|---|---|---|---|
Australia acute | Healthscope | In receivership since May 2025; remaining 31 hospitals to Calvary-led consortium | 37 hospitals, 19,000+ staff, ~650,000 patients pa at receivership; revenue n.d. | Formerly #2; weakened, now being restructured into not-for-profit |
Australia acute | Calvary Health Care | Not-for-profit (Catholic) | — | Consolidator of Healthscope assets; will become a larger rival |
Australia acute | St Vincent's Health Australia | Not-for-profit | — | Large Catholic network; public and private |
Australia acute | Epworth HealthCare, Cabrini, Mater, Healthe Care | Not-for-profit / private | — | Strong metropolitan positions (Melbourne, Brisbane) |
Australia day surgery | Independent day hospital operators | Various | Day surgeries received ~4% of PHI benefits vs 85% for private hospitals (12 months to Mar 2026) | Lower-cost substitutes for simple procedures |
UK acute | Spire Healthcare | LSE-listed | FY25 revenue £1,579.8m; adj. EBITDA £268.6m; ~30% of hospital revenue from NHS | Largest listed UK peer; less NHS-dependent than Ramsay UK; subject of 2026 takeover approach by Toscafund |
UK acute | Circle Health Group, Nuffield Health, HCA Healthcare UK | Private / charity / US-listed parent | — | HCA dominant in London private; Circle/Nuffield national networks |
UK mental health | Priory, Cygnet (UHS), Active Care Group | Private | — | Direct competitors to Elysium for NHS and local authority placements |
France | Elsan | Private | ~217 establishments, ~28,000 staff (company recruitment profile; not a primary filing) | #1/#2 French private hospital group alongside Ramsay Santé |
France | Vivalto Santé, Almaviva Santé | Private | — | Regional consolidators |
Nordics | Aleris, Praktikertjänst | Private / cooperative | — | Primary and specialist care competition |
Peer Comparison FY2026
| Metric | Ramsay Group FY26 | Ramsay Funding Group FY26 | Spire Healthcare FY25 (Dec YE) | Healthscope | Elsan |
|---|---|---|---|---|---|
Revenue | A$18,690m | A$9,423m | £1,579.8m | — | — |
Revenue growth | 5.1% (4.2% cc) | 4.9% (5.2% cc) | 4.5% | — | — |
EBITDA margin | 12.4% (reported) | 13.2% | 17.0% (adjusted) | — | — |
Underlying/adjusted EBIT margin | 6.2% | 8.8% | 9.5% (adjusted) | — | — |
R&D intensity | — | — | — | — | — |
Leverage | Consolidated net debt incl. leases/EBITDA 4.5x | 1.83x (covenant) | 2.0x net bank debt/EBITDA covenant |
| — |
“—” = not publicly disclosed.



